Drug Type Radiolabeled antibody, Therapeutic radiopharmaceuticals |
Synonyms [225Ac]-anti-EGFRvIII |
Target |
Action antagonists |
Mechanism EGFRvIII antagonists(Epidermal growth factor receptor variant III antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Glioblastoma | Preclinical | Canada | 14 Apr 2023 |






